This company listing is no longer active
DN Stock Overview
Operates as an integrated cannabis company. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Delta 9 Cannabis Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.01 |
| 52 Week High | CA$0.07 |
| 52 Week Low | CA$0.005 |
| Beta | 1.21 |
| 1 Month Change | 0% |
| 3 Month Change | -50.00% |
| 1 Year Change | -77.78% |
| 3 Year Change | -97.62% |
| 5 Year Change | -98.90% |
| Change since IPO | -99.65% |
Recent News & Updates
It's Unlikely That Shareholders Will Increase Delta 9 Cannabis Inc.'s (TSE:DN) Compensation By Much This Year
Jun 21
It's Down 29% But Delta 9 Cannabis Inc. (TSE:DN) Could Be Riskier Than It Looks
May 10Recent updates
It's Unlikely That Shareholders Will Increase Delta 9 Cannabis Inc.'s (TSE:DN) Compensation By Much This Year
Jun 21It's Down 29% But Delta 9 Cannabis Inc. (TSE:DN) Could Be Riskier Than It Looks
May 10Delta 9 Cannabis Inc.'s (TSE:DN) Shares Leap 122% Yet They're Still Not Telling The Full Story
Mar 26Market Might Still Lack Some Conviction On Delta 9 Cannabis Inc. (TSE:DN) Even After 122% Share Price Boost
Mar 26Is Delta 9 Cannabis (TSE:DN) Using Too Much Debt?
Sep 09Delta 9 Cannabis Inc. (TSE:DN) Not Doing Enough For Some Investors As Its Shares Slump 27%
Jul 28Does Delta 9 Cannabis (TSE:DN) Have A Healthy Balance Sheet?
Aug 19Is Delta 9 Cannabis (TSE:DN) A Risky Investment?
Jan 11Delta 9 Cannabis (TSE:DN) Is Making Moderate Use Of Debt
Sep 28Delta 9 Cannabis (TSE:DN) Is Carrying A Fair Bit Of Debt
Apr 08John Arbuthnot Is The Co-Founder of Delta 9 Cannabis Inc. (TSE:DN) And They Just Picked Up 1.0% More Shares
Dec 24
Shareholder Returns
| DN | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 0% | -3.4% | 2.2% |
| 1Y | -77.8% | -59.9% | 10.6% |
Return vs Industry: DN underperformed the Canadian Pharmaceuticals industry which returned 37.6% over the past year.
Return vs Market: DN underperformed the Canadian Market which returned 15.8% over the past year.
Price Volatility
| DN volatility | |
|---|---|
| DN Average Weekly Movement | 54.2% |
| Pharmaceuticals Industry Average Movement | 12.8% |
| Market Average Movement | 9.6% |
| 10% most volatile stocks in CA Market | 18.1% |
| 10% least volatile stocks in CA Market | 4.1% |
Stable Share Price: DN's share price has been volatile over the past 3 months.
Volatility Over Time: DN's weekly volatility has increased from 37% to 54% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 320 | John Arbuthnot | www.delta9.ca |
Delta 9 Cannabis Inc., together with its subsidiaries, operates as an integrated cannabis company. The company engages in the cultivation, processing, extraction, wholesale distribution, retail, and sale of medical and recreational cannabis products. Its products include dried cannabis flowers, pre-rolls, and dried sift cannabis, as well as oils, and extracted and derivative products.
Delta 9 Cannabis Inc. Fundamentals Summary
| DN fundamental statistics | |
|---|---|
| Market cap | CA$3.65m |
| Earnings (TTM) | -CA$19.60m |
| Revenue (TTM) | CA$70.65m |
0.1x
P/S Ratio-0.2x
P/E RatioIs DN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DN income statement (TTM) | |
|---|---|
| Revenue | CA$70.65m |
| Cost of Revenue | CA$58.10m |
| Gross Profit | CA$12.55m |
| Other Expenses | CA$32.15m |
| Earnings | -CA$19.60m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.054 |
| Gross Margin | 17.77% |
| Net Profit Margin | -27.74% |
| Debt/Equity Ratio | -447.3% |
How did DN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/08/25 01:50 |
| End of Day Share Price | 2024/07/15 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Delta 9 Cannabis Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kimberly Thompson-Hedlin | Canaccord Genuity |
| Siddharth Rajeev | Fundamental Research Corp. |
| Venkata Velagapudi | Research Capital Corporation |